Products
Commercialized Products
The Eurand product portfolio is focused primarily on the therapeutic category of gastrointestinal (GI) disorders and cystic fibrosis. Using our own sales and marketing team, Eurand is currently commercializing the portfolio for cystic fibrosis patients in the United States, and will expand the sales force to address the commercial needs as appropriate.
Zenpep®
The lead product in this portfolio is Zenpep® (pancrelipase) Delayed-Release Capsules. Marketed by Eurand in the U.S., ZENPEP is a pancreatic enzyme product (PEP) indicated for the treatment of exocrine pancreatic insufficiency (EPI) due to cystic fibrosis (CF) or other conditions such as chronic pancreatitis (CP), gastrointestinal surgery, and pancreatic cancer.
Read ZENPEP U.S. Important Safety Information.
SourceCF Product Portfolio
Eurand currently has a U.S. based commercial group of highly-experienced sales and sales support professionals dedicated to providing a portfolio of products and services to the CF community (patients, physicians and care givers). The SourceCF product portfolio most notably includes a portfolio of vitamins, designed specifically for CF patients, and the TRIO® (formerly marketed under the name eFlow® ) electronic nebulizer, a device frequently prescribed by physicians for CF patients who are required to administer therapies via nebulization. The sales professionals promoting the SourceCF product portfolio currently call on the Cystic Fibrosis Treatment Centers, as well as selected office-based gastroenterologists and pulmonologists, throughout the United States.
Product Licensing and Distribution Opportunities
The breadth and flexibility of our pharmaceutical technologies enable us to develop novel formulation solutions and products. Currently more than 40 products, spanning a range of therapeutic categories, have been developed by Eurand and are commercialized by our partners in different countries around the world.
Based on 2008 consolidated revenues.
Zenpep® is a registered trademark of Eurand Pharmaceuticals, Ltd.
